drugset
drugset / Trial / NCT03110900

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation

NCT03110900 ↗

Phase 4 Terminated 2 enrolled University of Arkansas Mount Sinai Hospital, Chicago · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to determine the noninferiority of inhaled loxapine compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes.

Timeline

Start
2017-09-30
Primary completion
2018-04-04
Completion
2018-04-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Haloperidol Other / unclassified 5 mg Intramuscular
Comparator Lorazepam Small molecule 2 mg Intramuscular
Subject loxapine Small molecule 10 mg Inhaled

Indications

No indication recorded.